EDESA BIOTECH, INC.: 10-Q filed 2019-02-05
What EDESA BIOTECH, INC. reported in its quarterly report filed 2019-02-05 (fiscal Q1 2019): 26 published measures, 54 facts as tagged in accession 0001144204-19-005062.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2019-02-05
- Fiscal period
- fiscal Q1 2019
- Accession
- 0001144204-19-005062 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All EDESA BIOTECH, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-12-31 | 10,499,948 | USD | |
| At 2018-09-30 | 11,779,975 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-12-31 | 9,907,925 | USD | |
| At 2018-09-30 | 11,286,590 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-12-31 | 7,364,662 | USD | |
| At 2018-09-30 | 4,225,521 | USD | |
| At 2017-12-31 | 4,369,671 | USD | |
| At 2017-09-30 | 4,570,951 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2018-12-31 | -1,405,704 | USD | 92 |
| 2017-10-01 to 2017-12-31 | -1,400,746 | USD | 92 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2018-12-31 | -1,308,836 | USD | 92 |
| 2017-10-01 to 2017-12-31 | -1,144,463 | USD | 92 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2018-12-31 | 5,666 | USD | 92 |
| 2017-10-01 to 2017-12-31 | 34,767 | USD | 92 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2018-12-31 | 53,033 | USD | 92 |
| 2017-10-01 to 2017-12-31 | 20,487 | USD | 92 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2018-12-31 | 4,473,298 | USD | 92 |
| 2017-10-01 to 2017-12-31 | 961,059 | USD | 92 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-12-31 | -51,836,696 | USD | |
| At 2018-09-30 | -50,430,992 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2018-12-31 | 800 | USD | 92 |
| 2017-10-01 to 2017-12-31 | 800 | USD | 92 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-12-31 | 1,022,212 | USD | |
| At 2018-09-30 | 1,062,195 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2018-12-31 | 27,039 | USD | 92 |
| 2017-10-01 to 2017-12-31 | 20,706 | USD | 92 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2018-12-31 | -1,406,321 | USD | 92 |
| 2017-10-01 to 2017-12-31 | -1,389,879 | USD | 92 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-12-31 | 9,462,396 | USD | |
| At 2018-09-30 | 10,655,984 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-12-31 | 592,023 | USD | |
| At 2018-09-30 | 493,385 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2018-12-31 | 1,459,354 | USD | 92 |
| 2017-10-01 to 2017-12-31 | 1,410,366 | USD | 92 |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-12-31 | 212,079 | USD | |
| At 2018-09-30 | 224,267 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2018-12-31 | 470,283 | USD | 92 |
| 2017-10-01 to 2017-12-31 | 631,034 | USD | 92 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-12-31 | 5,330,715 | shares | |
| At 2018-09-30 | 5,330,715 | shares |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-12-31 | 1,192,216 | USD | |
| At 2018-09-30 | 1,146,566 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2018-12-31 | 882,798 | USD | 92 |
| 2017-10-01 to 2017-12-31 | 678,481 | USD | 92 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2018-12-31 | 44,468 | USD | 92 |
| 2017-10-01 to 2017-12-31 | 49,309 | USD | 92 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2018-12-31 | 1,417 | USD | 92 |
| 2017-10-01 to 2017-12-31 | -10,067 | USD | 92 |
Income taxes paid, net
Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2018-12-31 | 0 | USD | 92 |
| 2017-10-01 to 2017-12-31 | 800 | USD | 92 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2018-12-31 | 30,469 | USD | 92 |
| 2017-10-01 to 2017-12-31 | 9,712 | USD | 92 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2018-12-31 | -12,188 | USD | 92 |
| 2017-10-01 to 2017-12-31 | 50,426 | USD | 92 |
Inspect the source
- Entity
- EDESA BIOTECH, INC. / CIK 0001540159
- Captured
- 2026-09-20T09:17:32.413Z
- SEC response SHA-256
0f44de1ccf1eff46a1af17dc21d4a3bb38216bbf46e813f5a136d29e08bfd65d
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001540159.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))